Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones. How the gut hormone glucagon-like peptide-2 (GLP-2) releases the triglyceride from the gut is not known. The research team in this study is interested in finding out how teduglutide (a degradation resistant form of GLP-2) releases stored triglyceride from the gut by studying samples from patients undergoing endoscopy and small bowel biopsy.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Collaborator: Kensington Screening Clinic
• Treatments: Glucagon; Glucagon-Like Peptide 1; Teduglutide

Criteria

Inclusion Criteria:

• Men and women, aged 18 to 60 years requiring endoscopy and duodenal biopsies for clinical indications, with no contraindications to the procedure, as judged by Dr. Bookman of the Kensington Screening Clinic, Toronto, ON, Canada

Exclusion Criteria:

• Patients with active inflammatory bowel disease

• Patients with pre-existing Celiac disease, exocrine pancreatic insufficiency or small bowel malabsorption

• Patients with active bowel malignancy

• Patients with diabetes mellitus or known/ suspected motility disorders of the gut

• Patients with decompensated liver disease

• Patients on ezetimibe or bile acid sequestrants

• Patients who are pregnant or breastfeeding.

• Patients with renal disease

• Patients on benzodiazepine

• Unstable cardiac or respiratory disease

• Any changes to medication in the preceding month